Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Miguel, a 63-year-old Los Angeles teacher, recently marked the 38th anniversary of his diagnosis with HIV. The doctor had told him he would be dead in a couple of years. He lived fearful that each ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Activities staff member Robert Hardrick teaches chair tai chi for residents of Broadway House for Continuing Care in New Jersey. (Photo: Courtesy of Broadway House) Nursing home patients with HIV may ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
News-Medical.Net on MSN
Investigating the impact of starting HIV drugs within days of infection
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback